Journal article

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

Hyuna Sung, Montserrat Garcia-Closas, Jenny Chang-Claude, Fiona M Blows, H Raza Ali, Jonine Figueroa, Heli Nevanlinna, Rainer Fagerholm, Paivi Heikkila, Carl Blomqvist, Graham G Giles, Roger L Milne, Melissa C Southey, Catriona McLean, Arto Mannermaa, Veli-Matti Kosma, Vesa Kataja, Reijo Sironen, Fergus J Couch, Janet E Olson Show all



BACKGROUND: Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours. METHODS: We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-p..

View full abstract


Awarded by Academy of Finland

Awarded by National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer

Awarded by R01 grants

Awarded by NHMRC

Awarded by National Institutes of Health/National Cancer Institute

Awarded by Yorkshire Cancer Research

Awarded by Cancer Research UK

Awarded by Academy of Medical Sciences (AMS)

Awarded by National Institute for Health Research

Awarded by The Francis Crick Institute

Awarded by National Breast Cancer Foundation


Funding Acknowledgements

The Helsinki Breast Cancer Study (HEBCS) thanks Kristiina Aittomaki, Kirsimari Aaltonen, Taru A Muranen, Karl von Smitten, and Irja Erkkila for their kind help with the patient samples and data. The Study of Epidemiology and Risk factors in Cancer Heredity (SEARCH) thanks Elena Provenzano and Marie Mack. The HEBCS was supported by The Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and The Nordic Cancer Union and the Sigrid Juselius Foundation. The Mayo Clinic Breast Cancer Study (MCBCS) was supported by The Breast Cancer Research Foundation, the National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), R01 grants (CA128978 and CA176785), and the Grohne Family. The Melbourne Collaborative Cohort Study (MCCS) was supported by The Cancer Council Victoria, VicHealth, NHMRC (209057, 251533, 396414, and 504711), Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index (NDI). The Nurses' Health Study (NHS) was supported by National Institutes of Health/National Cancer Institute (UM1 CA186107 and P01 CA 87969). The NHS thanks the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The Polish Breast Cancer Study (PBCS) was supported by Intramural Research Program of US NIH, NCI, Division of Cancer Epidemiology and Genetics (DCEG). The Sheffield Breast Cancer Study (SBCS) was supported by Yorkshire Cancer Research (S295, S299, and S305PA) and Sheffield Experimental Cancer Medicine Centre. The SEARCH was supported by Cancer Research UK (C490/A16561), the Biomedical Research Centre at the University of Cambridge. The Kuopio Breast Cancer Project (KBCP) was supported by The special Government Funding of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the strategic funding of the University of Eastern Finland.